Carla Bedford Dixon, MD
Hospice and Palliative Medicine · Alpharetta, GANPI 1801849716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 39.8% of the total. Reporting peaked in 2021 at $277 and has fallen 92.8% since, to $20 in 2023.
Across 43 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$272
- Lilly USA, LLC$146
- Bayer$100
- Novartis$74
- Johnson & Johnson$38
- Eisai Inc.$20
- plus $32 from 2 others
What the payments were for
- Food & beverage$682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $272 |
| Lilly USA, LLC | 9 | $146 |
| Bayer | 4 | $100 |
| Novartis | 4 | $74 |
| Johnson & Johnson | 2 | $38 |
| Eisai Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| AbbVie | 1 | $12 |
How this compares
$682 in reported general payments places this provider in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.
See all hospice and palliative medicine providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $10,042 |
| Memantine Hcl | 22 | $1,003 |
| Quetiapine Fumarate | 49 | $450 |
| Rosuvastatin Calcium | 15 | $431 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $313 |
| Tamsulosin Hcl | 15 | $293 |
| Hydralazine Hcl | 23 | $263 |
| Amlodipine Besylate | 53 | $231 |
| Oxybutynin Chloride | 25 | $186 |
| Levetiracetam | 19 | $174 |
| Omeprazole | 21 | $162 |
| Trazodone Hcl | 18 | $154 |
| Sertraline Hcl | 23 | $152 |
| Losartan Potassium | 15 | $133 |
| Levothyroxine Sodium | 23 | $123 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Alpharetta
- Veronica SudekumWarner Robins$7K
- Anthony EkwenchiAustell$5K
- Joshua JacksonAtlanta$5K
- Nokuthula MsimangaMarietta$3K
- Halima DaboikoKennesaw$3K
- Michelle ParkMarietta$2K
- Olumuyiwa AdeboyeLagrange$2K
- Mary KeithGainesville$2K
- Tanya NikolovaMarietta$1K
- Christina ChenMarietta$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.